Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 01:16PM ET
69.74
Dollar change
+0.05
Percentage change
0.07
%
IndexRUT P/E75.24 EPS (ttm)0.93 Insider Own19.21% Shs Outstand20.47M Perf Week0.61%
Market Cap1.47B Forward P/E13.83 EPS next Y5.04 Insider Trans-8.69% Shs Float17.03M Perf Month15.69%
Income17.15M PEG34.20 EPS next Q0.98 Inst Own67.25% Short Float1.54% Perf Quarter26.52%
Sales486.82M P/S3.02 EPS this Y-5.10% Inst Trans2.74% Short Ratio1.94 Perf Half Y15.79%
Book/sh21.13 P/B3.30 EPS next Y12.84% ROA2.24% Short Interest0.26M Perf Year80.58%
Cash/sh10.49 P/C6.65 EPS next 5Y2.20% ROE4.87% 52W Range36.99 - 70.81 Perf YTD26.48%
Dividend Est.- P/FCF13.35 EPS past 5Y-6.27% ROI2.30% 52W High-1.51% Beta0.80
Dividend TTM- Quick Ratio2.81 Sales past 5Y21.46% Gross Margin50.43% 52W Low88.54% ATR (14)1.72
Dividend Ex-Date- Current Ratio3.57 EPS Y/Y TTM130.72% Oper. Margin10.17% RSI (14)73.66 Volatility1.73% 3.04%
Employees642 Debt/Eq0.73 Sales Y/Y TTM53.87% Profit Margin3.52% Recom1.40 Target Price79.80
Option/ShortYes / Yes LT Debt/Eq0.73 EPS Q/Q113.69% Payout0.00% Rel Volume0.78 Prev Close69.69
Sales Surprise5.38% EPS Surprise16.96% Sales Q/Q39.71% EarningsFeb 29 BMO Avg Volume134.53K Price69.74
SMA203.40% SMA5014.33% SMA20021.88% Trades Volume63,135 Change0.07%
Date Action Analyst Rating Change Price Target Change
Mar-15-24Initiated CapitalOne Overweight $80
Aug-22-23Reiterated H.C. Wainwright Buy $60 → $73
Mar-01-23Initiated Guggenheim Buy $55
Sep-07-22Initiated H.C. Wainwright Buy $50
Nov-02-21Initiated Truist Buy $70
May-07-20Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-12-19Initiated Guggenheim Buy
May-10-19Downgrade Raymond James Strong Buy → Outperform $73 → $82
Oct-16-17Reiterated Canaccord Genuity Buy $60 → $66
Jul-31-17Initiated Canaccord Genuity Buy $60
Mar-27-24 06:15PM
06:50AM
Mar-26-24 09:15AM
Mar-22-24 09:54PM
Mar-21-24 06:00PM
09:30AM Loading…
Mar-20-24 09:30AM
Mar-19-24 06:15PM
Mar-14-24 09:40AM
Mar-08-24 11:54PM
Mar-06-24 11:29PM
12:00PM
Mar-04-24 08:28PM
Mar-01-24 09:30AM
09:15AM
08:35AM
12:27AM Loading…
12:27AM
Feb-29-24 09:30AM
07:56AM
07:15AM
07:11AM
06:50AM
Feb-28-24 10:30AM
Feb-26-24 09:15AM
Feb-22-24 10:00AM
Feb-21-24 06:00PM
Feb-20-24 06:50AM
Feb-12-24 06:00PM
Feb-07-24 06:50AM
Feb-05-24 06:00PM
Jan-29-24 06:00PM
06:50AM Loading…
06:50AM
Jan-23-24 06:50AM
Jan-22-24 06:00PM
Jan-19-24 06:59PM
06:15PM
Jan-16-24 06:50AM
Nov-22-23 09:26AM
Nov-19-23 07:00AM
Nov-17-23 05:11AM
Nov-09-23 09:42AM
Nov-08-23 03:11PM
09:30AM
07:08AM
06:50AM
Nov-02-23 10:00AM
Nov-01-23 06:00PM
10:01AM
Oct-30-23 06:50AM
Oct-25-23 06:50AM
Oct-20-23 06:00PM
Oct-19-23 06:15PM
Oct-13-23 06:00PM
Oct-06-23 06:00PM
Oct-05-23 06:15PM
Oct-02-23 06:50AM
Sep-29-23 06:00PM
Sep-22-23 04:19AM
Sep-21-23 06:00PM
Sep-20-23 06:15PM
Sep-18-23 04:05PM
Sep-14-23 06:00PM
Sep-12-23 06:50AM
Sep-11-23 02:43PM
Sep-08-23 08:50AM
Aug-29-23 09:15AM
Aug-28-23 06:50AM
Aug-25-23 12:00PM
10:00AM
06:39AM
Aug-24-23 06:50AM
Aug-23-23 08:50AM
06:50AM
Aug-16-23 09:15AM
Aug-11-23 09:40AM
Aug-10-23 09:15AM
Aug-09-23 09:30AM
08:15AM
07:06AM
06:50AM
Jul-31-23 11:06AM
07:17AM
Jul-24-23 06:00PM
Jul-18-23 06:00PM
09:40AM
Jul-11-23 06:15PM
Jun-27-23 07:12AM
Jun-22-23 09:40AM
Jun-21-23 08:00PM
09:15AM
Jun-20-23 11:31AM
Jun-06-23 12:37PM
09:40AM
May-22-23 06:34PM
May-18-23 09:40AM
May-16-23 04:05PM
May-15-23 06:50AM
May-12-23 07:03AM
May-11-23 04:01PM
May-09-23 02:32AM
May-08-23 01:17PM
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Mar 13 '24Sale66.5425016,63559,981Mar 13 04:48 PM
Gassert ChadSVP - CORP. DEV. & STRATEGYMar 11 '24Sale65.8120,0001,316,200273,226Mar 13 04:44 PM
CAREY STEPHEN P.SVP & CFOMar 11 '24Sale65.557,787510,438177,712Mar 11 06:39 PM
Lalwani NikhilPRESIDENT & CEOMar 08 '24Sale67.1316,2921,093,682411,629Mar 08 07:25 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSMar 08 '24Sale67.1710,000671,700832,620Mar 11 06:43 PM
Marken James G.SVP OPS & PROD DEVMar 07 '24Sale66.3724,3381,615,313124,492Mar 07 09:42 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSMar 07 '24Sale66.3515,0851,000,890842,620Mar 07 09:11 PM
Lalwani NikhilPRESIDENT & CEOMar 06 '24Sale65.5228,9651,897,787444,981Mar 08 07:25 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSMar 06 '24Sale65.4714,822970,396857,705Mar 07 09:11 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSMar 05 '24Sale65.3510,093659,578872,527Mar 07 09:11 PM
Mutz ChristopherHEAD OF RARE DISEASEMar 05 '24Sale66.005,000330,00087,387Mar 06 04:24 PM
Pera Antonio RDirectorMar 04 '24Sale65.207,000456,40026,627Mar 06 04:20 PM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Feb 13 '24Sale56.0425014,01036,799Feb 13 08:05 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJan 23 '24Sale56.4415,000846,600882,620Jan 23 05:32 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJan 22 '24Sale55.955,692318,467897,620Jan 23 05:32 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJan 19 '24Sale55.574,524251,399903,312Jan 23 05:32 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJan 18 '24Sale55.309,784541,055907,836Jan 18 06:20 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJan 17 '24Sale55.1110,000551,100917,620Jan 18 06:20 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJan 16 '24Sale55.635,000278,150927,620Jan 18 06:20 PM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Jan 12 '24Sale56.4325014,10837,049Jan 16 09:09 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSDec 19 '23Sale52.6525,0001,316,250932,620Dec 19 05:44 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSDec 18 '23Sale52.4413,026683,083957,620Dec 19 05:44 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSDec 15 '23Sale52.4411,974627,917970,646Dec 19 05:44 PM
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.Dec 11 '23Sale49.2125012,30237,299Dec 11 05:49 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSNov 17 '23Sale51.0013,000663,000982,620Nov 20 09:05 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSNov 16 '23Sale51.666,448333,104996,430Nov 16 06:11 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSNov 15 '23Sale53.647,647410,1851,002,878Nov 16 06:11 PM
Davis KristaSVP, CHIEF HR OFFICERNov 15 '23Sale53.812,622141,09032,587Nov 16 06:13 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSNov 14 '23Sale53.1722,0951,174,7911,010,525Nov 16 06:11 PM
Mutz ChristopherHEAD OF RARE DISEASENov 10 '23Sale52.473,000157,41063,607Nov 13 04:02 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSOct 19 '23Sale57.0610,000570,6001,032,620Oct 19 04:28 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSOct 18 '23Sale57.786,242360,6631,042,620Oct 19 04:28 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSOct 17 '23Sale58.538,758512,6061,048,862Oct 19 04:28 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSOct 16 '23Sale58.3113,063761,7041,057,620Oct 17 04:32 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSOct 13 '23Sale57.5811,937687,3321,070,683Oct 17 04:32 PM
Gassert ChadSVP - CORP. DEV. & STRATEGYOct 02 '23Sale56.4820,0001,129,600293,226Oct 03 08:00 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSep 19 '23Sale61.2325,3331,551,1401,082,620Sep 19 05:14 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSep 18 '23Sale61.648,425519,3171,107,953Sep 19 05:14 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSep 15 '23Sale62.8116,2421,020,1601,116,378Sep 19 05:14 PM
Gassert ChadSVP - CORP. DEV. & STRATEGYSep 01 '23Sale64.7020,0001,294,000313,226Sep 05 05:06 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSAug 29 '23Sale63.3725,0001,584,2501,132,620Aug 30 04:29 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSAug 28 '23Sale63.0625,0001,576,5001,157,620Aug 30 04:29 PM
Gutwerg OriSVP, GENERICSAug 23 '23Option Exercise31.4913,502425,17876,476Aug 25 04:22 PM
Marken James G.SVP OPS & PROD DEVAug 23 '23Option Exercise38.255,417207,224137,044Aug 25 04:17 PM
Gutwerg OriSVP, GENERICSAug 23 '23Sale62.3915,561970,85160,915Aug 25 04:22 PM
Marken James G.SVP OPS & PROD DEVAug 23 '23Sale63.003,932247,716133,112Aug 25 04:17 PM
MERIDIAN VENTURE PARTNERS II L10% OwnerAug 16 '23Sale58.50200,00011,700,0001,819,259Aug 16 08:00 PM
Lalwani NikhilPRESIDENT & CEOAug 15 '23Option Exercise29.0011,616336,864365,006Aug 15 08:39 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSAug 15 '23Sale61.6022,1101,361,9761,182,620Aug 16 07:07 PM
Lalwani NikhilPRESIDENT & CEOAug 15 '23Sale61.1311,616710,086353,390Aug 15 08:39 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSAug 14 '23Sale61.1527,8901,705,4741,204,730Aug 16 07:07 PM
CAREY STEPHEN P.SVP & CFOAug 14 '23Sale61.3717,6391,082,505155,839Aug 16 04:24 PM
Pera Antonio RDirectorAug 14 '23Sale60.373,000181,11033,627Aug 15 08:45 PM
Lalwani NikhilPRESIDENT & CEOAug 11 '23Sale57.7556,6663,272,462353,390Aug 15 08:39 PM
Gassert ChadSVP - CORP. DEV. & STRATEGYAug 01 '23Sale51.0620,0001,021,200333,226Aug 03 06:03 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJul 21 '23Sale52.5611,500604,4401,232,620Jul 21 07:15 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJul 20 '23Sale51.526,000309,1201,244,120Jul 21 07:15 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJul 19 '23Sale51.485,969307,2841,250,120Jul 21 07:15 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJul 18 '23Sale51.846,700347,3281,256,089Jul 18 08:06 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJul 17 '23Sale51.069,831501,9711,262,789Jul 18 08:06 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJul 14 '23Sale50.4310,000504,3001,272,620Jul 18 08:06 PM
Gassert ChadSVP - CORP. DEV. & STRATEGYJul 03 '23Sale53.4320,0001,068,600353,226Jul 06 04:15 PM
Gassert ChadSVP - CORP. DEV. & STRATEGYJun 22 '23Sale51.3220,0001,026,400373,226Jun 23 08:00 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJun 22 '23Sale51.3813,500693,6307,407Jun 22 08:00 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJun 21 '23Sale51.9511,843615,24420,907Jun 22 08:00 PM
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSJun 20 '23Sale51.9314,657761,13832,750Jun 22 08:00 PM